首页 > 最新文献

International journal of clinical and experimental pathology最新文献

英文 中文
Long noncoding RNA LINC00665 is a diagnostic biomarker that enhances cell proliferation and migration in hepatocellular carcinoma. 长链非编码RNA LINC00665是一种可促进肝癌细胞增殖和迁移的诊断性生物标志物。
IF 1.4 Q4 ONCOLOGY Pub Date : 2023-11-15 eCollection Date: 2023-01-01
Zhangfu Li, Jiangbei Yuan, Zilong Yan, Xu Liu, Jikui Liu

Background: This study aimed to evaluate the relationship between LINC00665 expression levels and the risk of hepatocellular carcinoma (HCC) in Chinese Han nationality patients and to explore the influence of LINC00665 dysregulation on the proliferation and migration potential of HCC cells.

Patients and methods: We investigated the expression of LINC00665 in The Cancer Genome Atlas (TCGA) database. Then, we confirmed the expression of LINC00665 in 54 pairs of surgical tissues from HCC patients and in liver cancer cell lines by quantitative real-time polymerase chain reaction. Furthermore, we manipulated the expression level of LINC00665 and examined the cell proliferation and migration abilities of HCC cells.

Results: In the TCGA cohort, a high level of LINC00665 in patients with HCC was significantly associated with tumor stage, tumor differentiation grade, and overall survival. In our HCC patient cohort, overexpression of LINC00665 in patients showed positive correlations with alpha-fetoprotein level, Barcelona Clinic Liver Cancer stage, and tumor differentiation grade. In addition, LINC00665 was upregulated in HCC cells, especially in cells with rapid growth rates and high migration abilities. A new LINC00665 isoform with a length of 1,371 nucleotides was identified in MHCC-97H cells. Interfering with LINC00665 expression weakened the proliferation and migration abilities of HCC cells. In contrast, LINC00665 overexpression enhanced proliferation and migration abilities.

Conclusion: LINC00665 was upregulated in HCC tissues and cells and might be used to predict a poor prognosis of HCC patients. In addition, LINC00665 may promote the malignant progression of HCC by enhancing proliferation and migration capacities.

背景:本研究旨在评价中国汉族患者中LINC00665表达水平与肝癌发生风险的关系,探讨LINC00665表达异常对肝癌细胞增殖和迁移潜能的影响。患者和方法:我们研究了LINC00665在癌症基因组图谱(TCGA)数据库中的表达。然后,我们通过实时定量聚合酶链反应,证实了LINC00665在54对HCC患者手术组织和肝癌细胞系中的表达。此外,我们通过调控LINC00665的表达水平,检测肝癌细胞的增殖和迁移能力。结果:在TCGA队列中,HCC患者中高水平的LINC00665与肿瘤分期、肿瘤分化分级和总生存期显著相关。在我们的HCC患者队列中,患者中LINC00665的过表达与甲胎蛋白水平、巴塞罗那临床肝癌分期和肿瘤分化等级呈正相关。此外,LINC00665在HCC细胞中表达上调,尤其是在生长速度快、迁移能力强的细胞中。在MHCC-97H细胞中发现了一个新的长度为1,371个核苷酸的LINC00665亚型。干扰LINC00665的表达可削弱HCC细胞的增殖和迁移能力。而过表达LINC00665则增强了细胞的增殖和迁移能力。结论:LINC00665在HCC组织和细胞中表达上调,可用于预测HCC患者预后不良。此外,LINC00665可能通过增强增殖和迁移能力来促进HCC的恶性进展。
{"title":"Long noncoding RNA LINC00665 is a diagnostic biomarker that enhances cell proliferation and migration in hepatocellular carcinoma.","authors":"Zhangfu Li, Jiangbei Yuan, Zilong Yan, Xu Liu, Jikui Liu","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the relationship between LINC00665 expression levels and the risk of hepatocellular carcinoma (HCC) in Chinese Han nationality patients and to explore the influence of LINC00665 dysregulation on the proliferation and migration potential of HCC cells.</p><p><strong>Patients and methods: </strong>We investigated the expression of LINC00665 in The Cancer Genome Atlas (TCGA) database. Then, we confirmed the expression of LINC00665 in 54 pairs of surgical tissues from HCC patients and in liver cancer cell lines by quantitative real-time polymerase chain reaction. Furthermore, we manipulated the expression level of LINC00665 and examined the cell proliferation and migration abilities of HCC cells.</p><p><strong>Results: </strong>In the TCGA cohort, a high level of LINC00665 in patients with HCC was significantly associated with tumor stage, tumor differentiation grade, and overall survival. In our HCC patient cohort, overexpression of LINC00665 in patients showed positive correlations with alpha-fetoprotein level, Barcelona Clinic Liver Cancer stage, and tumor differentiation grade. In addition, LINC00665 was upregulated in HCC cells, especially in cells with rapid growth rates and high migration abilities. A new LINC00665 isoform with a length of 1,371 nucleotides was identified in MHCC-97H cells. Interfering with LINC00665 expression weakened the proliferation and migration abilities of HCC cells. In contrast, LINC00665 overexpression enhanced proliferation and migration abilities.</p><p><strong>Conclusion: </strong>LINC00665 was upregulated in HCC tissues and cells and might be used to predict a poor prognosis of HCC patients. In addition, LINC00665 may promote the malignant progression of HCC by enhancing proliferation and migration capacities.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 11","pages":"332-343"},"PeriodicalIF":1.4,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138498364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathogenesis and treatment progress in age-related hearing loss: a literature review. 老年性听力损失的发病机制及治疗进展:文献综述。
IF 1.4 Q4 ONCOLOGY Pub Date : 2023-11-15 eCollection Date: 2023-01-01
Jianghui Yang, Zhangtao Shao, Duomi Zhang, Kai Wang

Age-related hearing loss (ARHL) is a progressive sensorineural hearing loss caused by age. The pathogenesis of ARHL is not completely clear at present, but it is closely related to auditory nerve degeneration, metabolic disorders, vitamin deficiency, and genetics, especially mitochondrial DNA damage. With the acceleration of industrialization and urbanization in our country, the impact of environmental noise is increasing, and ARHL has become one of the most important factors affecting the quality of life of the elderly in our country. Therefore, hearing intervention for patients with ARHL plays a crucial role in improving their quality of life. At present, the use of hearing aids and cochlear implants are the main means to treat the daily hearing difficulties and communication difficulties of patients with ARHL. However, in China, due to the economy, the concept of not wanting to treat the elderly, and other reasons, the hearing aid wearing rate compared to developed countries has significant differences. Cochlear implant is another option for patients with presbyacusis, and patients can obtain good hearing and speech recognition rate after surgery. At present, there is no definitive conclusion on whether the quality of life of patients after cochlear implantation has been improved, and this study will be reviewed based on previous relevant reports.

年龄相关性听力损失(age -related hearing loss, ARHL)是由年龄引起的进行性感音神经性听力损失。ARHL的发病机制目前尚不完全清楚,但与听神经退行性变、代谢紊乱、维生素缺乏、遗传、尤其是线粒体DNA损伤等密切相关。随着我国工业化、城市化进程的加快,环境噪声的影响越来越大,ARHL已成为影响我国老年人生活质量的重要因素之一。因此,对ARHL患者进行听力干预对改善其生活质量起着至关重要的作用。目前,使用助听器和人工耳蜗是治疗ARHL患者日常听力困难和沟通困难的主要手段。然而,在中国,由于经济、不愿对待老人的观念等原因,助听器佩戴率与发达国家相比有显著差异。耳蜗植入是老年性耳聋患者的另一种选择,术后患者可获得良好的听力和言语识别率。目前对于人工耳蜗植入术后患者的生活质量是否得到改善尚无明确结论,本研究将结合以往相关报道进行综述。
{"title":"Pathogenesis and treatment progress in age-related hearing loss: a literature review.","authors":"Jianghui Yang, Zhangtao Shao, Duomi Zhang, Kai Wang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Age-related hearing loss (ARHL) is a progressive sensorineural hearing loss caused by age. The pathogenesis of ARHL is not completely clear at present, but it is closely related to auditory nerve degeneration, metabolic disorders, vitamin deficiency, and genetics, especially mitochondrial DNA damage. With the acceleration of industrialization and urbanization in our country, the impact of environmental noise is increasing, and ARHL has become one of the most important factors affecting the quality of life of the elderly in our country. Therefore, hearing intervention for patients with ARHL plays a crucial role in improving their quality of life. At present, the use of hearing aids and cochlear implants are the main means to treat the daily hearing difficulties and communication difficulties of patients with ARHL. However, in China, due to the economy, the concept of not wanting to treat the elderly, and other reasons, the hearing aid wearing rate compared to developed countries has significant differences. Cochlear implant is another option for patients with presbyacusis, and patients can obtain good hearing and speech recognition rate after surgery. At present, there is no definitive conclusion on whether the quality of life of patients after cochlear implantation has been improved, and this study will be reviewed based on previous relevant reports.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 11","pages":"315-320"},"PeriodicalIF":1.4,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138498365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lenvatinib plus Immune Checkpoint Inhibitors versus Lenvatinib monotherapy as treatment for advanced hepatocellular carcinoma: a meta-analysis. Lenvatinib联合免疫检查点抑制剂与Lenvatinib单药治疗晚期肝细胞癌:荟萃分析
IF 1.4 Q4 ONCOLOGY Pub Date : 2023-11-15 eCollection Date: 2023-01-01
Xinlin Yu, Chun Wei, Ran Cui, Ou Jiang

Lenvatinib, an FDA-approved first-line oral multi-kinase inhibitor for advanced hepatocellular carcinoma (aHCC), has demonstrated promise for treatment. Nevertheless, findings from the Leap-002 study suggest that the addition of anti-vascular drugs to Lenvatinib may not yield significant improvements in survival rate. This meta-analysis aims to comprehensively assess the effectiveness of Lenvatinib, both as a standalone treatment and in combination with immune checkpoint inhibitors (ICIs), in managing advanced aHCC patients. We retrieved relevant studies published up to March 1, 2023, from databases such as PubMed, the Cochrane Library, Web of Science, and Embase. Subsequently, we conducted an analysis using REVMAN 5.3 and Stata MP 14.0 software, following quality assessment and data extraction procedures. A random effects model was employed to calculate the risk ratio (HR) using a 95% confidence interval (CI). The initial literature search yielded 921 results. However, after multiple rounds of exclusion and the removal of unrelated studies, 26 papers met the screening criteria. After a thorough examination of the full texts, we found that 8 studies met the analysis criteria. The combination of Lenvatinib with ICIs demonstrated significant improvement in overall survival (OS) (HR=1.53, 95% CI: 1.34-1.74; P<0.001) and progression-free survival (PFS) (HR=1.51, 95% CI: 1.34-1.72; P<0.001). Furthermore, subgroup analysis, categorized by the duration of follow-up, revealed that for the 3-year combined OS (HR=2.21, 95% CI: 1.79-2.73; Z=7.40, P<0.05), the combination therapy significantly outperformed monotherapy, leading to a 2.21-fold increase in OS for patients during the 3-year follow-up period. Nevertheless, for non-3-year combinations (HR=1.206, 95% CI: 1.020-1.425; Z=2.19, P<0.05), there was merely a 1.206-fold increase in effectiveness compared to single therapy for follow-ups of both longer and shorter durations. This might be attributed to the insufficient representation of HBV-related aHCC cases and the Asian population in the study, along with the increased availability of second-line treatment options for advanced cancer, which can influence the observed effectiveness of immunotherapy.

Lenvatinib是一种fda批准的用于晚期肝细胞癌(aHCC)的一线口服多激酶抑制剂,已经证明了治疗的前景。然而,Leap-002研究的结果表明,在Lenvatinib中加入抗血管药物可能不会显著提高生存率。本荟萃分析旨在全面评估Lenvatinib作为单独治疗和与免疫检查点抑制剂(ICIs)联合治疗晚期aHCC患者的有效性。我们从PubMed、Cochrane图书馆、Web of Science和Embase等数据库中检索了截至2023年3月1日发表的相关研究。随后,我们使用REVMAN 5.3和Stata MP 14.0软件进行分析,并进行质量评估和数据提取。采用随机效应模型,采用95%置信区间(CI)计算风险比(HR)。最初的文献检索产生了921个结果。然而,经过多轮排除和剔除无关研究后,有26篇论文符合筛选标准。在对全文进行全面检查后,我们发现有8项研究符合分析标准。Lenvatinib联合ICIs可显著改善总生存期(OS) (HR=1.53, 95% CI: 1.34-1.74;P
{"title":"Lenvatinib plus Immune Checkpoint Inhibitors versus Lenvatinib monotherapy as treatment for advanced hepatocellular carcinoma: a meta-analysis.","authors":"Xinlin Yu, Chun Wei, Ran Cui, Ou Jiang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Lenvatinib, an FDA-approved first-line oral multi-kinase inhibitor for advanced hepatocellular carcinoma (aHCC), has demonstrated promise for treatment. Nevertheless, findings from the Leap-002 study suggest that the addition of anti-vascular drugs to Lenvatinib may not yield significant improvements in survival rate. This meta-analysis aims to comprehensively assess the effectiveness of Lenvatinib, both as a standalone treatment and in combination with immune checkpoint inhibitors (ICIs), in managing advanced aHCC patients. We retrieved relevant studies published up to March 1, 2023, from databases such as PubMed, the Cochrane Library, Web of Science, and Embase. Subsequently, we conducted an analysis using REVMAN 5.3 and Stata MP 14.0 software, following quality assessment and data extraction procedures. A random effects model was employed to calculate the risk ratio (HR) using a 95% confidence interval (CI). The initial literature search yielded 921 results. However, after multiple rounds of exclusion and the removal of unrelated studies, 26 papers met the screening criteria. After a thorough examination of the full texts, we found that 8 studies met the analysis criteria. The combination of Lenvatinib with ICIs demonstrated significant improvement in overall survival (OS) (HR=1.53, 95% CI: 1.34-1.74; P<0.001) and progression-free survival (PFS) (HR=1.51, 95% CI: 1.34-1.72; P<0.001). Furthermore, subgroup analysis, categorized by the duration of follow-up, revealed that for the 3-year combined OS (HR=2.21, 95% CI: 1.79-2.73; Z=7.40, P<0.05), the combination therapy significantly outperformed monotherapy, leading to a 2.21-fold increase in OS for patients during the 3-year follow-up period. Nevertheless, for non-3-year combinations (HR=1.206, 95% CI: 1.020-1.425; Z=2.19, P<0.05), there was merely a 1.206-fold increase in effectiveness compared to single therapy for follow-ups of both longer and shorter durations. This might be attributed to the insufficient representation of HBV-related aHCC cases and the Asian population in the study, along with the increased availability of second-line treatment options for advanced cancer, which can influence the observed effectiveness of immunotherapy.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 11","pages":"321-331"},"PeriodicalIF":1.4,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138498363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiologic and clinicopathologic features of eosinophilic solid and cystic renal cell carcinoma: report of two cases and review of literature. 嗜酸性实性肾细胞癌和囊性肾细胞癌的影像学和临床病理特征:附2例报告并文献复习。
IF 1.4 Q4 ONCOLOGY Pub Date : 2023-10-15 eCollection Date: 2023-01-01
Jiejing Yin, Dina Zenezan, Khanh Duy Doan, Alisa Nobee, Shuanzeng Wei, Mehri Mollaee, Daniela M Proca

Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC) is a rare entity described in the latest WHO Classification of Urinary and Male Genital Tumours (2022 edition). It is a neoplasm that occurs most often in a sporadic setting, with no association with tuberous sclerosis complex (TSC). It typically presents as a well demarcated, non-encapsulated lesion, with solid and cystic architecture, composed of cells with voluminous eosinophilic cytoplasm and cytoplasmic stippling. Tumor cells are at least focally immunohistochemically (IHC) reactive for CK20. CD10 and Cathepsin K are positive in most cases. Consistent somatic mutually exclusive mutations in the TSC1 and TSC2 genes are detected in ESC RCC. We describe two ESC RCC cases diagnosed at our institution. Both cases occurred in female patients, ages of 33 and 64, respectively. Both patients had no evidence of TSC and both lesions were found incidentally, by imaging studies, at an early stage. Macroscopic and microscopic findings in both neoplasms were classic. One case was analyzed by molecular testing and TSC2 gene mutation was detected. Both cases had focal positivity of CD10 and Cathepsin K by IHC. Both tumors were stage pT1a at diagnosis and the patients remained free of disease after resection. It has been proposed that TSC1/2 can be a molecular marker for ESC RCC and be used to expand the morphologic spectrum of ESC RCC. As a novel rare subtype of renal cell carcinoma, with very limited data on molecular evaluation, it is useful to document these newly diagnosed ESC RCC cases.

嗜酸性实体和囊性肾细胞癌(ESC RCC)是最新的WHO泌尿和男性生殖器肿瘤分类(2022版)中描述的一种罕见的实体。它是一种最常发生在散发性环境中的肿瘤,与结节性硬化症(TSC)无关。典型表现为界限清晰、无包膜的病变,具有实性和囊性结构,由大量嗜酸性细胞质和细胞质斑点组成。肿瘤细胞至少对CK20有局部免疫组化反应。CD10和组织蛋白酶K在大多数病例中呈阳性。在ESC RCC中检测到一致的体细胞互斥突变TSC1和TSC2基因。我们描述了两个ESC RCC病例诊断在我们的机构。两例患者均为女性,年龄分别为33岁和64岁。两例患者均无TSC证据,两种病变都是在早期通过影像学检查偶然发现的。两例肿瘤的肉眼和显微镜表现均为典型。分子检测分析1例,检测到TSC2基因突变。两例患者免疫组化CD10和组织蛋白酶K均呈局灶性阳性。两例肿瘤在诊断时均为pT1a期,患者在切除后仍无病变。有研究认为TSC1/2可作为ESC RCC的分子标记物,用于扩展ESC RCC的形态学谱。作为一种新的罕见的肾细胞癌亚型,分子评估数据非常有限,记录这些新诊断的ESC RCC病例是有用的。
{"title":"Radiologic and clinicopathologic features of eosinophilic solid and cystic renal cell carcinoma: report of two cases and review of literature.","authors":"Jiejing Yin, Dina Zenezan, Khanh Duy Doan, Alisa Nobee, Shuanzeng Wei, Mehri Mollaee, Daniela M Proca","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC) is a rare entity described in the latest WHO Classification of Urinary and Male Genital Tumours (2022 edition). It is a neoplasm that occurs most often in a sporadic setting, with no association with tuberous sclerosis complex (TSC). It typically presents as a well demarcated, non-encapsulated lesion, with solid and cystic architecture, composed of cells with voluminous eosinophilic cytoplasm and cytoplasmic stippling. Tumor cells are at least focally immunohistochemically (IHC) reactive for CK20. CD10 and Cathepsin K are positive in most cases. Consistent somatic mutually exclusive mutations in the TSC1 and TSC2 genes are detected in ESC RCC. We describe two ESC RCC cases diagnosed at our institution. Both cases occurred in female patients, ages of 33 and 64, respectively. Both patients had no evidence of TSC and both lesions were found incidentally, by imaging studies, at an early stage. Macroscopic and microscopic findings in both neoplasms were classic. One case was analyzed by molecular testing and TSC2 gene mutation was detected. Both cases had focal positivity of CD10 and Cathepsin K by IHC. Both tumors were stage pT1a at diagnosis and the patients remained free of disease after resection. It has been proposed that TSC1/2 can be a molecular marker for ESC RCC and be used to expand the morphologic spectrum of ESC RCC. As a novel rare subtype of renal cell carcinoma, with very limited data on molecular evaluation, it is useful to document these newly diagnosed ESC RCC cases.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 10","pages":"303-308"},"PeriodicalIF":1.4,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134648868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Angiotensin-converting enzyme - human amniotic mesenchymal stem cells improve pulmonary vascular remodeling in rats with pulmonary hypertension by promoting angiogenesis and counteracting inflammation. 血管紧张素转换酶——人羊膜间充质干细胞通过促进血管生成和对抗炎症改善肺动脉高压大鼠肺血管重构。
IF 1.4 Q4 ONCOLOGY Pub Date : 2023-10-15 eCollection Date: 2023-01-01
Changfang Wu, Hao Liu, Mingchuan Ba, Jie Zha, Zhen Gao, Lijun Li, Peiyuan Xu, Minfei Li, Fusheng Cai, Mingjie Chen, Xiaona Wu, Lin Guo, Hongzhe Zhang

Objectives: Human Amniotic Mesenchymal Stem Cells (hAMSCs) have strong multidirectional differentiation ability. Studies have found that transfection of target genes into target cells by lentivirus can enhance the differentiation potential of the cells. Angiotensin-Converting Enzyme 2 (ACE2) was found to improve vascular remodeling. Research is lacking on ACE2-hAMSCs. Therefore, this study aimed to investigate the ability to improve pulmonary arterial hypertension using ACE2-hAMSCs.

Methods: Lentiviruses overexpressing ACE2 were mixed with hAMSCs. Then, ACE2-hAMSCs and hAMSCs with good growth in logarithmic growth phase were collected. We detected their migration and angiogenesis. RT-qPCR technology was used to detect the expression levels of genes related to angiogenesis, and inflammation in the two cell lines, and western-blotting was used to detect the expression levels of ACE2. As an animal study, 21 rats were randomly divided into four different groups. Right heart hypertrophy, pulmonary angiogenesis, and serum inflammatory factors were measured before dissection. H&E staining was used to observe the inflammatory infiltration of lung tissues.

Results: The migration and angiogenesis of ACE2-hAMSCs were strongerthan that of hAMSCs alone. The expressions of genes in ACE2-hAMSCs were higher, and the expression of ACE2 protein in ACE2-hAMSCs was less. H&E staining showed that the inflammatory infilration of lung tissue in ACE2-hAMSCs groups was significantly improved. In addition, the ACE2-hAMSCs group had stronger pro-angiogenesis and anti-inflammatory effects.

Conclusion: These results suggest that ACE2-hAMSCs can repair pulmonary vascular endothelial cell injury caused by pulmonary hypertension by promoting angiogenesis and anti-inflammatory ability. This shows that ACE2-hAMSCs have stronger ability to improve pulmonary vascular remodeling than hAMSCs alone.

目的:人羊膜间充质干细胞(hAMSCs)具有较强的多向分化能力。研究发现,慢病毒将靶基因转染到靶细胞中,可以增强细胞的分化潜能。血管紧张素转换酶2 (ACE2)可改善血管重构。ACE2-hAMSCs缺乏相关研究。因此,本研究旨在探讨ACE2-hAMSCs改善肺动脉高压的能力。方法:将过表达ACE2的慢病毒与hAMSCs混合。然后收集ACE2-hAMSCs和对数生长期生长良好的hAMSCs。我们检测了它们的迁移和血管生成。采用RT-qPCR技术检测两种细胞系中血管生成、炎症相关基因的表达水平,western-blotting检测ACE2的表达水平。作为动物实验,21只大鼠被随机分为四组。解剖前测量右心肥厚、肺血管生成及血清炎性因子。H&E染色观察肺组织炎症浸润情况。结果:ACE2-hAMSCs的迁移和血管生成强于单独的hAMSCs。ACE2- hamscs中基因表达量较高,ACE2蛋白表达量较少。H&E染色显示,ACE2-hAMSCs组肺组织炎症浸润明显改善。此外,ACE2-hAMSCs组具有更强的促血管生成和抗炎作用。结论:ACE2-hAMSCs可通过促进血管生成和抗炎能力修复肺动脉高压引起的肺血管内皮细胞损伤。这表明ACE2-hAMSCs比单独的hAMSCs具有更强的改善肺血管重构的能力。
{"title":"Angiotensin-converting enzyme - human amniotic mesenchymal stem cells improve pulmonary vascular remodeling in rats with pulmonary hypertension by promoting angiogenesis and counteracting inflammation.","authors":"Changfang Wu, Hao Liu, Mingchuan Ba, Jie Zha, Zhen Gao, Lijun Li, Peiyuan Xu, Minfei Li, Fusheng Cai, Mingjie Chen, Xiaona Wu, Lin Guo, Hongzhe Zhang","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>Human Amniotic Mesenchymal Stem Cells (hAMSCs) have strong multidirectional differentiation ability. Studies have found that transfection of target genes into target cells by lentivirus can enhance the differentiation potential of the cells. Angiotensin-Converting Enzyme 2 (ACE2) was found to improve vascular remodeling. Research is lacking on ACE2-hAMSCs. Therefore, this study aimed to investigate the ability to improve pulmonary arterial hypertension using ACE2-hAMSCs.</p><p><strong>Methods: </strong>Lentiviruses overexpressing ACE2 were mixed with hAMSCs. Then, ACE2-hAMSCs and hAMSCs with good growth in logarithmic growth phase were collected. We detected their migration and angiogenesis. RT-qPCR technology was used to detect the expression levels of genes related to angiogenesis, and inflammation in the two cell lines, and western-blotting was used to detect the expression levels of ACE2. As an animal study, 21 rats were randomly divided into four different groups. Right heart hypertrophy, pulmonary angiogenesis, and serum inflammatory factors were measured before dissection. H&E staining was used to observe the inflammatory infiltration of lung tissues.</p><p><strong>Results: </strong>The migration and angiogenesis of ACE2-hAMSCs were strongerthan that of hAMSCs alone. The expressions of genes in ACE2-hAMSCs were higher, and the expression of ACE2 protein in ACE2-hAMSCs was less. H&E staining showed that the inflammatory infilration of lung tissue in ACE2-hAMSCs groups was significantly improved. In addition, the ACE2-hAMSCs group had stronger pro-angiogenesis and anti-inflammatory effects.</p><p><strong>Conclusion: </strong>These results suggest that ACE2-hAMSCs can repair pulmonary vascular endothelial cell injury caused by pulmonary hypertension by promoting angiogenesis and anti-inflammatory ability. This shows that ACE2-hAMSCs have stronger ability to improve pulmonary vascular remodeling than hAMSCs alone.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 10","pages":"282-293"},"PeriodicalIF":1.4,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134648923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adult cerebral high-grade glioneuronal tumor with perivascular or pseudopapillary growth co-existing with low-grade tumor: a case report. 成人大脑高级别胶质神经元肿瘤伴血管周围或假乳头状生长,并伴有低级别肿瘤1例。
IF 1.4 Q4 ONCOLOGY Pub Date : 2023-10-15 eCollection Date: 2023-01-01
Masayuki Shintaku, Makoto Ohta, Hideo Chihara, Hideaki Yokoo, Yuri Noda, Koji Tsuta

An unusual, small cell-predominant, high-grade glioneuronal tumor in the occipital lobe of a 49-year-old man that co-existed with a low-grade tumor is reported. The tumor consisted of two distinct components: the major component was a dense proliferation of primitive small cells showing bidirectional neuronal and glial differentiation; and the minor component consisted of a proliferation of well-differentiated astrocytes intermingled with mature neuronal cells. In the former component, perivascular pseudorosette-like or pseudopapillary growth reminiscent of ependymoma or papillary glioneuronal tumor (PGNT), respectively, was prominent, and hypertrophic astrocytic cells were located just outside the central blood vessels. Small cells were immunoreactive for Olig2, synaptophysin, and, less frequently, for glial fibrillary acidic protein. The low-grade component included Rosenthal fibers, hemosiderin deposition, and perivascular lymphocytic infiltration, thus closely resembling ganglioglioma. Cytogenetic studies did not demonstrate any mutations or rearrangements of the genes IDH1, IDH2, H3F3A, BRAF, FGFR1, or TERT promoter. The tumor recurred and spread along the ventricular surface three years after total removal. The small cell-predominant, high-grade component was considered to have evolved from the ganglioglioma-like, low-grade component. The histopathologic resemblance of the high-grade component to PGNT was a special feature.

本文报告一位49岁男性枕叶发生罕见、小细胞为主、高级别胶质神经元肿瘤并伴有低级别肿瘤。肿瘤由两个不同的组成部分组成:主要组成部分是原始小细胞的密集增殖,表现为双向神经元和胶质分化;次要成分是分化良好的星形胶质细胞与成熟的神经元细胞混合增殖。在前一组中,血管周围假性结节样生长或假乳头状生长,分别使人联想到室管膜瘤或乳头状胶质神经元瘤(PGNT),肥大的星形细胞位于中央血管外。小细胞对Olig2、synaptophysin有免疫反应,对胶质纤维酸性蛋白的免疫反应较少。低级别成分包括罗森塔尔纤维、含铁血黄素沉积和血管周围淋巴细胞浸润,因此与神经节胶质瘤非常相似。细胞遗传学研究未发现IDH1、IDH2、H3F3A、BRAF、FGFR1或TERT启动子有任何突变或重排。肿瘤复发,并沿心室表面扩散三年后全部切除。小细胞为主的高级别成分被认为是从神经节胶质瘤样的低级别成分进化而来的。高级别成分与PGNT的组织病理学相似性是一个特殊的特征。
{"title":"Adult cerebral high-grade glioneuronal tumor with perivascular or pseudopapillary growth co-existing with low-grade tumor: a case report.","authors":"Masayuki Shintaku, Makoto Ohta, Hideo Chihara, Hideaki Yokoo, Yuri Noda, Koji Tsuta","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An unusual, small cell-predominant, high-grade glioneuronal tumor in the occipital lobe of a 49-year-old man that co-existed with a low-grade tumor is reported. The tumor consisted of two distinct components: the major component was a dense proliferation of primitive small cells showing bidirectional neuronal and glial differentiation; and the minor component consisted of a proliferation of well-differentiated astrocytes intermingled with mature neuronal cells. In the former component, perivascular pseudorosette-like or pseudopapillary growth reminiscent of ependymoma or papillary glioneuronal tumor (PGNT), respectively, was prominent, and hypertrophic astrocytic cells were located just outside the central blood vessels. Small cells were immunoreactive for Olig2, synaptophysin, and, less frequently, for glial fibrillary acidic protein. The low-grade component included Rosenthal fibers, hemosiderin deposition, and perivascular lymphocytic infiltration, thus closely resembling ganglioglioma. Cytogenetic studies did not demonstrate any mutations or rearrangements of the genes <i>IDH1, IDH2, H3F3A, BRAF, FGFR1,</i> or <i>TERT</i> promoter. The tumor recurred and spread along the ventricular surface three years after total removal. The small cell-predominant, high-grade component was considered to have evolved from the ganglioglioma-like, low-grade component. The histopathologic resemblance of the high-grade component to PGNT was a special feature.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 10","pages":"294-302"},"PeriodicalIF":1.4,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extrarenal Wilms tumor of the recto-vaginal septum with BRCA2 gene mutation: a case report. 伴有BRCA2基因突变的直肠-阴道间隔肾外Wilms肿瘤1例报告。
IF 1.4 Q4 ONCOLOGY Pub Date : 2023-10-15 eCollection Date: 2023-01-01
Qijun Chen, Kaixuan Yang, Xiao Tang

Extrarenal Wilms tumor (ERWT) is rare, and its occurrence in the adult recto-vaginal septum is even more uncommon. Importantly, instances of a BRCA2 gene mutation associated with ERWT have not been documented. In this report, we present an unusual case of ERWT situated in the recto-vaginal septum of a 49-year-old woman, accompanied by a concurrent BRCA2 gene mutation. After the tumor's second recurrence, the patient experienced symptomatic relief after administering poly (ADP-ribose) polymerase (PARP) inhibitor therapy. Given the limited exposure and understanding of optimal treatment strategies for this distinct tumor, there is a definite need to accumulate further clinical experiences and insight. Consequently, we propose that genetic testing be considered in cases involving tumor recurrence or metastasis, since this may offer valuable information for identifying targets for therapeutic intervention.

肾外肾母细胞瘤(ERWT)是罕见的,其发生在成人直肠-阴道间隔更是罕见。重要的是,与ERWT相关的BRCA2基因突变的实例尚未被记录。在本报告中,我们提出了一个不寻常的病例ERWT位于直肠阴道间隔的一个49岁的妇女,伴有并发BRCA2基因突变。肿瘤第二次复发后,患者接受聚(adp -核糖)聚合酶(PARP)抑制剂治疗后症状缓解。鉴于有限的曝光和对这种独特肿瘤的最佳治疗策略的理解,明确需要积累进一步的临床经验和见解。因此,我们建议在涉及肿瘤复发或转移的病例中考虑基因检测,因为这可能为确定治疗干预的目标提供有价值的信息。
{"title":"Extrarenal Wilms tumor of the recto-vaginal septum with <i>BRCA2</i> gene mutation: a case report.","authors":"Qijun Chen, Kaixuan Yang, Xiao Tang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Extrarenal Wilms tumor (ERWT) is rare, and its occurrence in the adult recto-vaginal septum is even more uncommon. Importantly, instances of a BRCA2 gene mutation associated with ERWT have not been documented. In this report, we present an unusual case of ERWT situated in the recto-vaginal septum of a 49-year-old woman, accompanied by a concurrent <i>BRCA2</i> gene mutation. After the tumor's second recurrence, the patient experienced symptomatic relief after administering poly (ADP-ribose) polymerase (PARP) inhibitor therapy. Given the limited exposure and understanding of optimal treatment strategies for this distinct tumor, there is a definite need to accumulate further clinical experiences and insight. Consequently, we propose that genetic testing be considered in cases involving tumor recurrence or metastasis, since this may offer valuable information for identifying targets for therapeutic intervention.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 10","pages":"309-313"},"PeriodicalIF":1.4,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134648924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune-related gene prognostic index (IRGPI) for lung adenocarcinoma predicts patient prognosis and immunotherapy response. 肺腺癌免疫相关基因预后指数(IRGPI)预测患者预后和免疫治疗反应。
IF 1.4 Q4 ONCOLOGY Pub Date : 2023-10-15 eCollection Date: 2023-01-01
Zheng Zhu, Wei Feng, Xiao-Yan Tan, Pin-Chao Gu, Wei Song, Hai-Tao Ma

Objective: We searched for a predictive biomarker that also predicts whether patients would benefit from immune checkpoint blockade (ICB) treatment from a few angles, because existing biomarkers no longer wholly replicate the interconnections of distinctive elements in the tumor microenvironment (TME).

Methods: We identified 55 pivotal IRGs by performing a WGCNA and univariate Cox regression analysis on a lung adenocarcinoma dataset from the TCGA database. The IRGPI model was then constructed using multivariate Cox regression analysis, which identified 16 genes and verified the use of the GSE68465 database. The AUC of the IRGPI was compared to those of the current biomarkers to determine its predictive potential. Then we examined the molecular and immunological properties of ICB and assessed its effectiveness using CTLA4 expression and TIDE.

Results: Patients with a high IRGPI had a later clinical stage, more severe symptoms, and a worse prognosis. Patients with a low IRGPI had a higher immune escape potential and were less responsive to immunotherapy.

Conclusion: The IRGPI may be a biomarker for determining the prognosis of patients and whether they respond favorably to ICB therapy.

目的:我们寻找一种预测性生物标志物,它也可以从几个角度预测患者是否会从免疫检查点阻断(ICB)治疗中获益,因为现有的生物标志物不再完全复制肿瘤微环境(TME)中不同元素的相互联系。方法:我们通过对TCGA数据库中的肺腺癌数据集进行WGCNA和单变量Cox回归分析,确定了55个关键IRGs。然后利用多变量Cox回归分析构建IRGPI模型,鉴定出16个基因,并验证了GSE68465数据库的使用。将IRGPI的AUC与当前生物标志物的AUC进行比较,以确定其预测潜力。然后,我们检测了ICB的分子和免疫学特性,并通过CTLA4表达和TIDE评估了其有效性。结果:高IRGPI患者临床分期较晚,症状较重,预后较差。低IRGPI的患者有较高的免疫逃逸潜力,对免疫治疗反应较差。结论:IRGPI可能是判断患者预后和是否对ICB治疗反应良好的生物标志物。
{"title":"Immune-related gene prognostic index (IRGPI) for lung adenocarcinoma predicts patient prognosis and immunotherapy response.","authors":"Zheng Zhu, Wei Feng, Xiao-Yan Tan, Pin-Chao Gu, Wei Song, Hai-Tao Ma","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>We searched for a predictive biomarker that also predicts whether patients would benefit from immune checkpoint blockade (ICB) treatment from a few angles, because existing biomarkers no longer wholly replicate the interconnections of distinctive elements in the tumor microenvironment (TME).</p><p><strong>Methods: </strong>We identified 55 pivotal IRGs by performing a WGCNA and univariate Cox regression analysis on a lung adenocarcinoma dataset from the TCGA database. The IRGPI model was then constructed using multivariate Cox regression analysis, which identified 16 genes and verified the use of the GSE68465 database. The AUC of the IRGPI was compared to those of the current biomarkers to determine its predictive potential. Then we examined the molecular and immunological properties of ICB and assessed its effectiveness using CTLA4 expression and TIDE.</p><p><strong>Results: </strong>Patients with a high IRGPI had a later clinical stage, more severe symptoms, and a worse prognosis. Patients with a low IRGPI had a higher immune escape potential and were less responsive to immunotherapy.</p><p><strong>Conclusion: </strong>The IRGPI may be a biomarker for determining the prognosis of patients and whether they respond favorably to ICB therapy.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 10","pages":"260-281"},"PeriodicalIF":1.4,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134648925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protective effect of mesenchymal stem cell-conditioned medium on hepatic cell apoptosis after acute liver injury [Retraction]. 间充质干细胞条件培养基对急性肝损伤后肝细胞凋亡的保护作用[牵回]。
IF 1.4 Q4 ONCOLOGY Pub Date : 2023-10-15 eCollection Date: 2023-01-01

[This retracts the article on p. 831 in vol. 6, PMID: 23638214.].

[本文撤回了第6卷第831页的文章,PMID: 23638214]。
{"title":"Protective effect of mesenchymal stem cell-conditioned medium on hepatic cell apoptosis after acute liver injury [Retraction].","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>[This retracts the article on p. 831 in vol. 6, PMID: 23638214.].</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 10","pages":"314"},"PeriodicalIF":1.4,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134648926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicopathologic characteristics of neuroendocrine tumors with assessment by digital image analysis for Ki-67 index with a focus on the gastroenteropancreatic tract: a single-center study. 神经内分泌肿瘤的临床病理特征与Ki-67指数的数字图像分析评估,重点关注胃肠胰道:一项单中心研究。
IF 1.4 Q4 ONCOLOGY Pub Date : 2023-09-15 eCollection Date: 2023-01-01
Ji Hyun Park, Su-Jin Shin, Nara Jeon, Beom Jin Lim

Objectives: Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that arise at various sites throughout the body. The gastroenteropancreatic (GEP) tract is the most common site of NETs. We investigated the clinicopathologic features of patients with GEP-NETs and the utility of digital image analysis, which was compared to eyeball estimation, a conventional method used to determine the Ki-67 labeling index.

Methods: The clinicopathologic data of GEP-NET patients at Gangnam Severance Hospital from January 2008 to October 2019 were retrospectively analyzed. Each case was reclassified according to the 2019 World Health Organization classification system, to which the classification of grade 3 was added. Comparisons between eyeball estimation and the digital image analysis method for Ki-67 index assessment were performed by calculating Cohen's kappa (k) coefficient.

Results: In total, 345 patients with GEP-NETs were enrolled. The mean age was 49.3 (range 13-79) years, with more male (61.1%) than female patients. The primary tumor sites were the rectum (70.1%), pancreas (12.5%), stomach (6.7%), and duodenum (5.8%). Overall, 298 (86.4%), 35 (10.1%), 2 (0.6%), and 10 (2.9%) patients exhibited grade 1, 2, and 3 and neuroendocrine carcinoma, respectively. Statistical analysis revealed that age > 50 years, tumor size > 2 cm, and presence of lymphovascular invasion, nodal metastasis, and distant metastasis were significantly associated with short overall survival. Additionally, 283 patients underwent digital image analysis of the Ki-67 index, and substantial agreement was found between the two methods (κ value: 0.765).

Conclusions: Eyeball estimation revealed non-inferior results compared with digital image analysis. Further research is needed to evaluate the possibility of using digital image analysis as an alternative analysis method.

目的:神经内分泌肿瘤(NETs)是一组异质性肿瘤,发生在全身不同部位。胃肠胰道是NETs最常见的部位。我们研究了GEP-NETs患者的临床病理特征和数字图像分析的实用性,并将其与眼球估计(一种用于确定Ki-67标记指数的传统方法)进行了比较。方法:回顾性分析2008年1月至2019年10月江南Severance医院GEP-NET患者的临床病理资料。每个病例都根据2019年世界卫生组织的分类系统进行了重新分类,其中增加了3级分类。通过计算Cohen’s kappa(k)系数对Ki-67指数评估的眼球估计和数字图像分析方法进行比较。结果:共有345名GEP NETs患者入选。平均年龄49.3岁(13-79岁),男性患者(61.1%)多于女性患者。主要肿瘤部位为直肠(70.1%)、胰腺(12.5%)、胃(6.7%)和十二指肠(5.8%)。总的来说,298名(86.4%)、35名(10.1%)、2名(0.6%)和10名(2.9%)患者分别表现为1、2和3级神经内分泌癌。统计分析显示,年龄>50岁,肿瘤大小>2cm,淋巴管浸润、淋巴结转移和远处转移与总生存期短显著相关。此外,283名患者接受了Ki-67指数的数字图像分析,发现两种方法之间基本一致(κ值:0.765)。结论:与数字图像分析相比,眼球估计显示的结果并不差。需要进一步的研究来评估使用数字图像分析作为替代分析方法的可能性。
{"title":"Clinicopathologic characteristics of neuroendocrine tumors with assessment by digital image analysis for Ki-67 index with a focus on the gastroenteropancreatic tract: a single-center study.","authors":"Ji Hyun Park,&nbsp;Su-Jin Shin,&nbsp;Nara Jeon,&nbsp;Beom Jin Lim","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that arise at various sites throughout the body. The gastroenteropancreatic (GEP) tract is the most common site of NETs. We investigated the clinicopathologic features of patients with GEP-NETs and the utility of digital image analysis, which was compared to eyeball estimation, a conventional method used to determine the Ki-67 labeling index.</p><p><strong>Methods: </strong>The clinicopathologic data of GEP-NET patients at Gangnam Severance Hospital from January 2008 to October 2019 were retrospectively analyzed. Each case was reclassified according to the 2019 World Health Organization classification system, to which the classification of grade 3 was added. Comparisons between eyeball estimation and the digital image analysis method for Ki-67 index assessment were performed by calculating Cohen's kappa (k) coefficient.</p><p><strong>Results: </strong>In total, 345 patients with GEP-NETs were enrolled. The mean age was 49.3 (range 13-79) years, with more male (61.1%) than female patients. The primary tumor sites were the rectum (70.1%), pancreas (12.5%), stomach (6.7%), and duodenum (5.8%). Overall, 298 (86.4%), 35 (10.1%), 2 (0.6%), and 10 (2.9%) patients exhibited grade 1, 2, and 3 and neuroendocrine carcinoma, respectively. Statistical analysis revealed that age > 50 years, tumor size > 2 cm, and presence of lymphovascular invasion, nodal metastasis, and distant metastasis were significantly associated with short overall survival. Additionally, 283 patients underwent digital image analysis of the Ki-67 index, and substantial agreement was found between the two methods (κ value: 0.765).</p><p><strong>Conclusions: </strong>Eyeball estimation revealed non-inferior results compared with digital image analysis. Further research is needed to evaluate the possibility of using digital image analysis as an alternative analysis method.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 9","pages":"225-234"},"PeriodicalIF":1.4,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560883/pdf/ijcep0016-0225.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41199982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International journal of clinical and experimental pathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1